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Infants with hypoplastic left heart syndrome require an initial Norwood operation, fol-
lowed some months later by a stage 2 palliation (S2P). The timing of S2P is critical for
the operation’s success and the infant’s survival, but the optimal timing, if one exists, is
unknown. We attempt to estimate the optimal timing of S2P by analyzing data from the
Single Ventricle Reconstruction Trial (SVRT), which randomized patients between two dif-
ferent types of Norwood procedure. In the SVRT, the timing of the S2P was chosen by
the medical team; thus with respect to this exposure, the trial constitutes an observational
study, and the analysis must adjust for potential confounding. In Chapter 1, we propose
an extended propensity score analysis that describes the time to surgery as a function
of confounders in a discrete competing-risk model. We then apply inverse probability
weighting to estimate a spline hazard model for predicting survival from the time of S2P.
In Chapter 2, we address same question by multiply imputing the potential post-S2P sur-
vival outcomes with a lognormal model under the Rubin Causal Model framework. With
this approach, it is straightforward to estimate the causal effect of S2P timing on post-S2P
survival by directly comparing the imputed potential outcomes. We examine the sensitivity
of these results by applying a more flexible model that assumes proportional hazards as
a function of S2P time, with a restricted cubic spline (RCS) for the baseline hazard. Our
analysis suggests that S2P conducted at 6 months after the Norwood gives the patient
v
the best post-S2P survival.
In Chapter 3, we build a new 10-year ASCVD (atherosclerotic cardiovascular disease)
risk prediction model for Veterans Affairs (VA) women based on data from the VA national
EHR (Electronic Health Records) database.
vi
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CHAPTER 1
Estimating the Optimal Timing of Surgery from Observational Data
1.1. Introduction
Hypoplastic left heart syndrome (HLHS) is a congenital condition that afflicts roughly
1,000 US newborns each year [31]. Because children with this syndrome have severely
compromised blood oxygenation and circulation, without prompt treatment it is uniformly
fatal. In the 1970s, children with HLHS received only supportive care, and all died as
neonates. The advent of the Norwood procedure followed by stage 2 palliation (S2P),
introduced in the early 1980s, has led to vastly improved survival, with many patients now
living to adulthood [56].
Nevertheless, HLHS patients continue to face substantial mortality risk, particularly
in the interim between the Norwood and S2P operations. For example, in the Single
Ventricle Reconstruction Trial, which compared two variants of the Norwood procedure,
mortality before post-Norwood discharge was 16%, and a further 12% died between the
Norwood discharge and S2P [12, 19, 44]. There is reason to believe that appropriately
timing the S2P can further improve patient outcomes. Although no single time may be
optimal in all cases, it is desirable to identify a default time that gives superior results.
The choice of the optimal time to conduct the S2P is a causal question that refers
to selecting the best from a range of potential outcomes. As there has been no ran-
domized trial of S2P timing, bias from confounding can affect any data we have on this
question. Previous authors have described methods to investigate the causal effect of a
1
time-dependent treatment on the distribution of an outcome. Robins et al [35] proposed
the marginal structural model, which allows for improved adjustment for confounding with
time-dependent treatment or covariates. Hu et al [22] developed a structural proportional
hazards model to characterize the effect of treatment initiation time on survival, using it
to select the timing of antiretroviral therapy initiation for patients who are co-infected with
HIV and tuberculosis.
Meza et al [28] estimated the optimal S2P timing without applying techniques from
causal modeling. They used parametric hazard analysis to model transplant-free survival
(TFS) from (1) Norwood procedure to S2P and (2) S2P to 3 years. They determined
the optimal timing of S2P by generating nomograms of risk-adjusted TFS vs. the interval
from the Norwood procedure to S2P. Their method does not address confounding bias;
for further discussion see Section 1.4.5 below.
Some currently available methods [22, 35] address the situation where there is one
type of treatment with no competing risks. By contrast, HLHS patients after the initial
Norwood surgery face four possible mutually exclusive events: elective S2P, non-elective
S2P, cardiac transplantation, or death before S2P. An S2P is “elective” if regular monitor-
ing of the patient suggests that the team can safely schedule the procedure after a brief
time, often a week or two. It is “non-elective” if monitoring suggests that the operation
must take place urgently. Because only one of these four events can occur, we identify
the pre-S2P/post-Norwood outcomes as competing risks.
To estimate without bias the effect of S2P timing on post-S2P survival, one must adjust
for potential confounding effects of the choice of treatment. Within the framework of the
Rubin Causal Model (RCM), one accomplishes this by modeling the selection of timing
as a function of potential confounders in a propensity score analysis. In the HLHS setting
we cannot create propensity scores from a logistic regression for treatment assignment
because i) there are several possible times of S2P surgery, and ii) the possible events
constitute competing risks. We therefore propose to use an extension of propensity score
2
analysis that assumes multiple treatments [23, 24, 36], basing our scores on a discrete-
time competing risk analysis of the possible post-Norwood but pre-S2P outcomes. This
model produces a generalized propensity score, from which we compute inverse proba-
bility weights that we apply in a proportional hazards regression [7] to describe the effect
of S2P timing on post-S2P survival.
1.2. The Single Ventricle Reconstruction Trial
Our data are from the US National Heart, Lung, & Blood Institute Pediatric Heart Net-
work Single Ventricle Reconstruction Trial (SVRT), conducted at 15 US centers between
2005 and 2008 [30]. Its primary aim was to compare one-year transplant-free survival
of newborns who were randomly assigned to have their Norwood procedure either with
a modified Blalock-Taussig shunt (MBTS) or a right ventricle-to-pulmonary artery (RVPA)
shunt. Among 548 randomized HLHS patients who had operative data and follow-up,
139 died prior to S2P, and 9 received a heart transplant. The remaining 400 underwent
S2P (Figure 1.1). The medical team determined the timing based on clinical assessment,
transcutaneous oxygen saturation measurements, and echocardiographic findings.
The SVRT data set includes information on pre-Norwood medical history, Norwood
procedure and post-operative course, S2P operation and post-operative course, postna-
tal echocardiograms (pre- and post-Norwood and pre-S2P), pre-S2P angiography, and
cardiac catheterization [28]. We have divided the S2P timing (measured in months from
the date of the Norwood procedure) into six categories: 1–3 months, 4 months, 5 months,
6 months, 7 months, and ≥ 8 months. This gives adequate numbers of patients in each
category to render the generalized propensity score model estimable.
3
Figure 1.1: Treatment and outcome patterns in the SVRT data
1.3. A Model-Based Analysis Method
Our modeling strategy involves three elements: An extended propensity score analy-
sis, a competing-risks model that permits estimation of propensity scores, and a hazard
model relating S2P time to post-S2P survival.
1.3.1. The generalized propensity score
Assume a collection of subjects i = 1, . . . , n, for each of whom we observe a baseline
covariate vector Xi and a treatment Zi ∈ {1, . . . ,M}. We moreover suppose that each
has a notional vector {Ti(z)}Mz=1, where Ti(z) represents the post-S2P survival outcome
should patient i receive treatment z. Only Ti(Zi) is observed; the other potential outcomes
are counterfactuals. In this setting, Imai et al [23] define the generalized propensity score
4




1, if Zi = z,
0, otherwise
is an indicator function for the treatment for subject i. The generalized propensity score
has similar properties to the conventional propensity score [36]:
1. It is a balancing score:
Di(z) ⊥ Xi | ei(z,Xi) ∀z;
that is, given the generalized propensity score, the actual treatment and the covari-
ate vector are independent.
2. It renders treatment assignment unconfounded (ignorable):
Di(z) ⊥ Ti(z) | ei(z,Xi) ∀z;
that is, the potential outcomes and the actual treatment assignment are conditionally
independent given the generalized propensity score.
1.3.2. A competing-risks model for post-Norwood disposition
After undergoing the Norwood procedure, patients go on to experience either S2P or
death/heart transplantation. We denote Z to be the discrete time since Norwood of the
first occurrence of one of these events, and we denote R to be the type of event that
occurs: R = 1 for S2P and R = 2 for death/heart transplantation. This event R is distinct
from the post-S2P survival outcome. Data permitting, we can re-define R as R = 1 for
elective S2P, R = 2 for non-elective S2P, and R = 3 for death/heart transplantation to
achieve a finer subgroup analysis.
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As only one of these post-Norwood/pre-S2P events R can occur, we specify for Z a
competing-risks model that constitutes the basis of our propensity score analysis. Let
hr(z|x) denote the cause-specific hazard function for discrete time Z ∈ {1, . . . ,M} of
event R ∈ {1, . . . , J}; that is,
hr(z|x) = Pr(Z = z,R = r|Z ≥ z,X = x),
where x is a vector of covariates. The overall event hazard is h(z|x) =
∑J
r=1 hr(z|x). The
probability that an event of type r takes place at time z is
Pr(Z = z,R = r|X = x) = hr(z|x)S(z|x), (1.1)
where S(z|x) is the survival function S(z|X = x) = Pr(Z ≥ z|X = x) =
∏z−1
v=1 (1− h (v|x)).
Tutz et al [49] proposed a multinomial logistic model for cause-specific hazards with
discrete Z:
hr(z|x) =
exp (β0zr + xβr)
1 +
∑J
j=1 exp (β0zj + xβj)
, (1.2)
where β0zr stands for the cause-specific baseline hazard function at time z for event r,
and βr is the vector of cause-specific coefficients. This model assumes a time-constant
effect of covariates on each cause-specific hazard. The probability that no event occurs
at time z, given survival to that point, is







j=1 exp (β0zj + xβj)






= β0zr + xβr. (1.3)
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We identify the generalized propensity score as the probability of undergoing S2P at
time z given the covariate vector x, Pr(Z = z,R = 1|X = x). The discrete S2P time is
regarded as the treatment Z in the generalized propensity score described above. This
makes the generalized propensity score for outcome r in our analysis
e
(r)
i (z, x) = Pr(Zi = z,Ri = r|Xi = x).
(As the r is understood in subsequent analyses, we henceforth drop the superscript on
ei.) In a weighted propensity-score analysis, the weight function is the inverse of the





We denote this the raw weight for subject i. Because analyses using small raw weights
can be unstable, it is often preferable to use the stabilized weight [35]
w∗i =
Pr(Zi = z,Ri = r)
ei(Zi, Xi)
.
Here, Pr(Zi = z,Ri = 1) is the marginal probability that subject i received S2P at time
z ∈ {1, 2, . . . , 6}. We estimate this probability by averaging the estimated values of the
terms in Equation (1.1) for R = 1 at each time z over the S2P patients.
1.3.3. A spline model for post-S2P survival
We describe the effect of S2P timing Z on post-S2P survival T by a proportional haz-
ards model, adjusting for confounding by inverse generalized propensity score weighting
[6, 35, 55]. The hazard at time t is
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λ(t|R = 1; z, α) = λ0(t|R = 1) exp[g(z;α)], (1.4)
where λ0(t|R = 1) is the post-S2P baseline hazard at time t for patients having S2P, and
g(z;α) is a linear spline function in z (the S2P treatment time) with coefficient vector α:




Here, K1, ..., KQ are preselected knots and (v)+ = max(0, v). In the linear spline model,
Z is still discrete with possible values 1 to 6 corresponding to the six time categories
introduced in Section 1.2. We use the Cox model with inverse generalized propensity
score weighting because it is flexible and easy to estimate.
Three key points motivate our model choice:
1. We interpret Z as a discrete, ordinal representation of time, because this confers
protection against potential distorting effects of small numbers of outlying S2P times.
2. The use of a regression spline to define the dependence of the hazard on Z is
simply a device for parameterizing the model, analogous to the choice of a contrast
matrix in an analysis of variance. Although spline regression typically presupposes
a continuous predictor, it need not. By selecting Model (1.4) from among the linear
splines with knots at all Z values, we obtain a parsimonious representation of the
hazard function.
3. Although we consider Z here to be discrete, the model is readily applicable, without
modification of notation or code, in situations where Z is continuous.
In the Appendix A we present sensitivity analyses that demonstrate robustness to the
parameterization of the hazard model and to the use of continuous rather than discrete
Z.
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For the generalized propensity score model, we assume that there is no unmeasured
confounding, effectively that the vector x contains all potential confounders. This as-
sumption is questionable, as it would be in any analysis of observational data. For the
Cox model with weighting, we assume that censoring time is independent of the potential
mortality outcome given the propensity score. Because censoring of post-S2P survival
in SVRT is essentially administrative, this assumption is plausible. Under these assump-
tions, Model (1.4) encodes the counterfactual hazard rate of T (z) at t, which we will con-
sider as our causal quantity of interest. We are interested in finding the z that minimizes
this quantity.
1.3.4. Estimating the spline model for post-S2P survival
Suppose we have n∗ subjects as above and let ∆i be an indicator that equals 1 if
subject i dies after S2P and 0 otherwise. T ∗ = min(T,C) is the observed post-S2P
follow-up time and C is the censoring time. The risk set Ri is the set of subjects who
are alive just prior to an observed time of death ti. The categorical variable Z is the S2P
time as above. It is reasonable to start with a saturated linear spline model and select a
subset of influential knots by the LASSO [47]. We compute the coefficients α̂ (we show in
































q = 2, 3, . . . , Q+ 1.
(1.6)
Here w∗i is the stabilized weight for subject i. One can calculate standard errors for
{α̂s}Q+1s=1 by inverting the weighted information matrix. The weighting creates a pseudo-
population consisting of w∗i (or wi) copies of each subject i [35]. The intuition is that if the
propensity score for an observed S2P timing is small, its behavior is underrepresented in
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the sample, and assigning it a large weight reduces bias.
Having estimated the model, we identify the optimal S2P timing by plotting the mortality
hazard linear spline against z and finding its minimum. We create a 100(1−α) confidence
interval for the optimal z by bootstrapping the data [11] and identifying the α/2 and (1 −
α/2) quantiles of the bootstrap distribution of optimal S2P times.
1.4. Application to the SVRT Data
1.4.1. Preliminary analyses
Descriptive statistics by Norwood outcome appear in Table 1.1. We note that children
who underwent S2P were heavier at birth and slightly younger at the time of the Norwood
procedure and post-Norwood discharge. Roughly 60% were male and 80% were white in
all groups. Subjects who underwent RVPA were more likely to survive to S2P.
Table A.1 (see Appendix A.2) presents baseline data for the 400 S2P recipients,
grouped by S2P time. Mean birth weight and mean age at the Norwood procedure are
similar across S2P time groups. The mean Norwood discharge age is younger for those
having the S2P 4–6 months after the Norwood procedure. Figure A.1 (see Appendix A.1)
shows histograms of S2P time stratified by elective status. Most non-elective S2Ps oc-
curred within 6 months of the Norwood, whereas elective procedures occurred on average
later.
1.4.2. Generalized propensity score analysis
All patients who underwent the Norwood procedure proceeded to either S2P or death
or cardiac transplantation without S2P. We used the discrete-time competing-risk model
described above to estimate generalized propensity scores for time of S2P, with time
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Table 1.1: Descriptive statistics by outcome of the Norwood procedure
S2P Death/Txa
Variable Values (n = 400) (n = 148)
Discrete
Sex M 252(63.0%) 87(58.8%)
F 148(37.0%) 61(41.2%)
Race White 323(80.8%) 112(75.7%)
Black 59(14.7%) 27(18.2%)
Other 18(4.5%) 9(6.1%)
Norwood treatment MBTS 177(44.3%) 91(61.5%)
RVPA 223(55.7%) 57(38.5%)
Prenatal diagnosis of congenital heart disease Y 312(78.0%) 107(72.3%)
N 88(22.0%) 41 (27.7%)
Aortic atresia Y 243(60.8%) 99(66.9%)
N 157(39.2%) 49(33.1%)
Obstructed pulmonary venous return Y 6(1.5%) 13(8.8%)
N 394(98.5%) 135(91.2%)
Continuousb
Birth weight (gm) 3157(518) 2961(576)
Norwood age (days) 6.7(4.0) 6.8(4.2)
Norwood discharge age (days) 40.1(32.9) 42.1(46.1)
aDeath or heart transplantation
bValues given as mean(SD)
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origin the date of the Norwood procedure. We used as covariates sex, race, birth weight,
Norwood procedure randomization arm, prenatal diagnosis of congenital heart disease,
aortic atresia, obstructed pulmonary venous return, and Norwood discharge age. These
are all baseline covariates.
As described above, we obtain the generalized propensity score from Equation (1.1)
with R = 1 (for S2P) or with R = 2 (for death/heart transplantation). To fit the multino-
mial logit model (1.3) and achieve the cause-specific hazard (1.2) in discrete time, we
transformed the data into a long form, with one row per patient per time category. The es-
timated model coefficients from the SVRT data are those shown under the column “Truth”
in the simulation settings of Table 1.2.
Figure 1.2 shows the result of the extended propensity score analysis. The average
probability of having S2P by month, adjusted for covariates and averaged over all patients,
rises steadily until month 5 then declines to near 0. Evidently, most patients undergo the
S2P from about 4 to 7 months after the Norwood. The probability of heart transplantation
or death declines over time from its modal value at months 1–3.
The stabilized weight for each subject used in the following analysis is the product of
the inverse generalized propensity score and the marginal probability of having S2P. We
coded the 6 possible values of S2P time Z as 1 to 6. These marginal probabilities are
0.053, 0.127, 0.173, 0.138, 0.045, 0.029. Probabilities in Figure 1.2 represent all 548
subjects.
1.4.3. Assessing covariate balance
Table A.1 shows that the covariates sex, race, Norwood arm, and Norwood discharge
age are poorly balanced across timing groups. We checked covariate balance given the
generalized propensity score using the method of Zhu et al [58]. This involved creating a
synthetic data set by sampling 5,000 observations with replacement from the original data
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Figure 1.2: Average probability of competing events over time, estimated from the
competing-risk model with outcomes S2P and death/transplantation
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set with sampling probability equal to the stabilized weight. We then evaluated balance in
the synthetic data by calculating Cramér’s V statistic and setting the threshold at 0.1. Our
analysis suggested that balance was improved and was acceptable for further analysis.
1.4.4. Optimal S2P time
Our best-fitting survival model, evaluated by AIC, placed knots at z = 3 and z = 4,
corresponding to times 5 and 6 months. This gave estimated post-S2P survival hazard
λ(t|R = 1; z) = λ0(t|R = 1) exp [−0.19z − 0.66(z − 3)+ + 0.99(z − 4)+] .
The standard errors for the coefficients are, respectively, 0.072, 0.125 and 0.210. The
log hazard ratio over Z appears in Figure 1.3, with month 6 as the reference level. From
this plot, patients receiving the S2P intervention at 6 months after the Norwood have the
lowest hazard and therefore the best survival prospects. A 95% bootstrap confidence
interval for the optimal S2P timing is [5,∞). The estimated 1-year post-S2P mortality risk
(with 95% CI) associated with this result appears in Table A.3.
In a sensitivity analysis, we analyzed post-S2P survival including only elective or only
non-elective S2P patients (Figures A.3 and A.4) by re-categorizing R: R = 1 for elective
S2P, R = 2 for non-elective S2P, and R = 3 for death/heart transplantation. The optimal
S2P timing for elective S2P patients is 6 months after the Norwood procedure with 95%
bootstrap confidence interval [5, 7] months. By contrast, for non-elective S2P, the optimal
S2P timing is as late as possible with confidence interval [4,∞). A possible explanation
for this difference is that patients are selected for non-elective S2P because their gen-
eral health condition is poor and unstable; that is, patients who are doing worse should
undergo the S2P later.
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Figure 1.3: Log mortality hazard ratio as a function of S2P timing, including all S2P pa-
tients
In this relatively small clinical trial, there is little power to evaluate the interaction be-
tween Norwood procedure type (MBTS or RVPA) and S2P timing. Unsurprisingly, when
we conducted this analysis we found no significant effect.
In the Appendix A, we present a sensitivity analysis that compares the discrete spline
model to i) a model with indicators for the discrete Z values and ii) a model that smooths
the hazard function with a linear spline on the continuous Z values. In the latter approach,
although Z is taken to be continuous, we use the weights from the discrete-Z competing-
risk model. Results show modest sensitivity to the hazard-modeling method when taking
Z to be discrete. Estimates were similar when considering Z to be continuous, although
this model exhibited greater sensitivity to the selection of knots.
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1.4.5. Comparison with the analysis of Meza et al.
Meza et al [28] analyzed the effect of S2P timing on survival using a “parametric haz-
ard” analysis. They began by constructing separate parametric models for transplant-free
survival after the Norwood procedure and survival after S2P. They then transformed the
post-S2P survival analysis results into a 3-year transplant-free survival plot over Norwood-
S2P intervals to determine the optimal S2P timing, concluding that the interval 3 to 6
months is best. We have some concerns about this analysis: First, it does not explic-
itly adjust for covariate effects on treatment assignment, as we do in our generalized
propensity score analysis; thus their estimates may be sensitive to potential model mis-
specification [10]. Second, when creating the nomogram to find the optimal S2P timing,
they failed to consider the competing risks of death and heart transplantation. Finally,
they did not distinguish elective from non-elective S2P, potentially biasing their estimate
toward the earlier times often seen in non-elective S2P operations.
1.4.6. A re-analysis using the method of Hu et al.
Although not designed to describe sequential treatments like the HLHS program, the
structural proportional hazards model of Hu et al [22] is potentially applicable to the SVRT
data. Identifying HIV/TB co-infection with the Norwood procedure, and antiretroviral ther-
apy with S2P, and censoring other Norwood outcomes (death and heart transplantation),
we were able to apply their method to the SVRT data. Results appear in Figure A.2, with
confidence intervals obtained by bootstrapping. This analysis gives an optimal S2P timing
at month 6 (95% CI [6, 8]), later than the Meza finding.
Our method differs from that of Hu et al [22] in several ways. First, we have formulated
the problem as one of maximizing post-S2P survival (T ) rather than pre- plus post-S2P
survival (Z + T ). We believe this better reflects the clinical situation, where the idea is to
produce the best possible long-term survival. The novelty in our method is in its use of a
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competing risk framework to model treatment selection.
We note moreover that our data differ in kind from those of Hu et al., who had a large
number of subjects with censored Z (we have none) and only a small fraction of deaths
prior to treatment (4%, compared to 26% in our sample).
1.5. Simulations
We performed simulations to evaluate the reliability of estimation of the discrete com-
peting risk model and the Cox model with weighting in samples of moderate size (see
Appendix A.4). We ran 2,000 replicates of each model with sample sizes of 500 and
1,000, setting true parameters to their estimates from the SVRT data. The main outcome
was the coverage probability of nominal 95% confidence intervals for the model parame-
ters.
Table 1.2 shows results for the competing-risk model. With n = 500, coverage proba-
bilities exceed 90%, but some are noticeably below 95%. When we increase the sample
size to n = 1, 000, all coefficients have coverage probability near the nominal 95%.
Table 1.3 shows results for simulated post-S2P survival data. Here λ∗ is the scale
parameter and γ∗ is the shape parameter for the underlying survival distribution. We fixed
the spline knots at 3 and 4; thus, there are three parameters (α1,α2,α3) in total for the
spline function g(·) discussed in Section 1.3.3. Table 1.3 shows that using the raw weight
wi leads to unacceptably low coverage probabilities, whereas using the stabilized weight
w∗i gives coverage probabilities close to 95%. Coverage probabilities are noticeably closer
to the nominal level when the sample size is n = 1, 000.
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Table 1.2: Monte Carlo coverage probabilities of nominal 95% confidence intervals for
parameters of the competing-risk model
Coverage Probability (%)
Outcome Variable Coefficient Truth n = 500 n = 1, 000
S2P Intercept Z = 1 β011 −4.126 94.3 95.5
Intercept Z = 2 β021 2.352 93.1 95.1
Intercept Z = 3 β031 3.210 92.9 95.0
Intercept Z = 4 β041 3.914 93.4 94.7
Intercept Z = 5 β051 3.856 92.5 95.5
Intercept Z = 6 β061 4.237 93.0 96.0
Sex:F β11 0.052 91.5 94.9
Race:W β12 −0.037 91.7 94.9
Race:B β13 −0.406 92.0 95.0
Norwood treatment:RVPA β14 0.184 90.6 94.6
Birth weight β15 0.0002 91.3 96.2
Prenatal diagnosis of congenital heart disease:Yes β16 0.028 92.6 94.9
Aortic atresia:Yes β17 −0.050 91.6 95.1
Obstructed pulmonary venous return:Yes β18 0.200 93.6 94.5
Norwood procedure discharge age β19 −0.008 92.2 95.3
Death/Heart Transplant Intercept Z = 1 β012 0.748 93.4 95.3
Intercept Z = 2 β022 −0.645 93.0 95.8
Intercept Z = 3 β032 −0.938 92.7 95.7
Intercept Z = 4 β042 −1.506 91.9 95.4
Intercept Z = 5 β052 0.301 92.1 94.8
Intercept Z = 6 β062 0.102 92.4 95.7
Sex:F β21 0.211 90.5 94.6
Race:W β22 −0.176 91.3 95.3
Race:B β23 −0.071 90.5 95.7
Norwood treatment:RVPA β24 −0.591 92.0 94.8
Birth weight β25 −0.001 92.8 94.7
Prenatal diagnosis of congenital heart disease:Yes β26 0.163 91.5 95.9
Aortic atresia:Yes β27 −0.148 91.4 95.7
Obstructed pulmonary venous return:Yes β28 1.906 91.7 95.9
Norwood procedure discharge age β29 −0.004 91.4 95.2
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Table 1.3: Monte Carlo coverage probabilities of nominal 95% confidence inter-
vals for parameters of the post-S2P survival model
Coverage Probability (%)
Rawa Stbb Raw Stb
Survival distribution Coefficient True value n = 500 n = 500 n = 1, 000 n = 1, 000
Exponential (λ∗ = 1) α1 −0.19 51.5 94.0 54.0 95.3
α2 −0.66 55.8 93.9 58.6 94.2
α3 0.99 53.1 93.5 59.5 95.7
Weibull (λ∗ = 1, γ∗ = 1.5) α1 −0.19 54.4 92.5 55.3 94.4
α2 −0.66 57.8 93.2 60.2 96.1
α3 0.99 59.0 94.5 58.5 95.8
Gompertz (λ∗ = 1, γ∗ = 1) α1 −0.19 61.0 94.7 60.6 94.5
α2 −0.66 52.3 93.0 57.2 94.8




SVRT was effectively an observational study with respect to the choice of S2P timing;
accordingly, we have proposed a generalized propensity score analysis to remove poten-
tial confounding of S2P time and post-S2P survival. The first stage involves estimating
a discrete competing-risks model to create a generalized propensity score for predicting
time of the S2P. The second stage involves estimating a Cox model predicting survival
from S2P time, using the inverse propensity scores as weights. Our analysis of the SVRT
data suggests that conducting the S2P at 6 months after the Norwood is optimal for limit-
ing mortality risk.
Originally, we treated death and transplant as separate competing risks. Because
only a few patients experienced transplant prior to S2P, we ultimately combined these two
events into a single category. Although we did this largely for convenience, in fact death
and transplant both represent treatment failure; in many cases a child who died would
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have instead received a transplant if a donor heart had been available at the time.
A key parameter in determining the suitability of a post-Norwood-procedure patient for
S2P is the pulmonary vascular resistance (PVR), a marker of maturity of the infant’s cir-
culatory system. Surgeons are unwilling to perform S2P until the PVR has declined below
a safe level. Because the SVRT was not designed to study the timing of S2P, only one
PVR measurement field appears in the data set, and almost half of these observations
are missing (“PVR measurement not done”) [28]. Therefore, we did not include the PVR
in our analysis — a potentially serious limitation of this study.
Because there are no widely accepted guidelines for checking balance of categorical
covariates over a multi-level treatment, we assessed covariate balance using the Cramér’s
V statistic [8]. The investigation of methods for assessing balance in these complex
situations is a potential topic for further study.
We conclude that the optimal timing of S2P is roughly 6 months post-Norwood, with a
95% confidence interval of 5 to infinity. This fits into the current clinical experience. The
reason for this strange upper limit is that the last category of our discrete S2P time is
“≥ 8”. Because a large majority of HLHS patients undergo S2P within one year of the
Norwood procedure, it is difficult to assess mortality for higher values of Z. Our interval
is slightly later than Meza’s suggestion of 3–6 months, but similar to our reinterpretation
of the SVRT data using the method of Hu et al [22], which gave the interval 6–8 months.
With the substantial risk of death, transplant, and unscheduled S2P, the “optimal” time is
at best a target that medical teams will aspire to achieve in less complicated cases.
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CHAPTER 2
Estimating the Optimal Timing of Surgery by Imputing Potential Outcomes
2.1. Introduction
Hypoplastic left heart syndrome (HLHS), a complex of congenital conditions charac-
terized by underdevelopment or absence of the left ventricle, is uniformly fatal without
prompt treatment. The combination of the Norwood procedure followed by stage 2 pallia-
tion (S2P), introduced in the early 1980s, has led to vastly improved survival, with many
patients now living to adulthood [56]. It is known that the choice of S2P timing affects
the post-S2P survival time, although it is not known which time, if any, is best. A key po-
tential data source for answering this question is the Single Ventricle Reconstruction Trial
(SVRT), a study that randomized HLHS patients between versions of the Norwood pro-
cedure and assigned a range of S2P times according to clinical criteria [30]. We describe
the SVRT in greater detail in Section 2.3.1.
Estimating the optimal S2P time involves a causal comparison of outcomes under the
range of possible times of treatment. In the parlance of the Rubin causal model [25], a
potential outcome is a value of the outcome of interest under a particular choice of treat-
ment. In HLHS, the outcome of interest is the post-S2P survival time, and the potential
outcomes are the values of this variable under the different possible S2P times. Because
in the SVRT the S2P timing was not randomly assigned, confounding can bias estima-
tion. Current methods to investigate the causal effect of a time-dependent treatment on
the distribution of an outcome mainly rely on the marginal structural model [22, 35]. These
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methods use an inverse probability weighted marginal proportional hazard model to re-
move the confounding bias. Westreich et al [53] discuss causal inference by imputation of
the potential outcomes using multiple imputation or the g-formula [34] based on time-fixed
dichotomous treatment. They impute the potential outcomes independently, rather than
simultaneously, because the original data contain no information about the joint distribu-
tion of potential outcomes. We have proposed a generalized propensity score analysis,
using inverse propensity score weighting to eliminate confounding bias in estimation of the
optimal S2P timing [4]. The method regards post-Norwood/pre-S2P outcomes, including
death, heart transplantation and S2P, as competing risks, deriving generalized propensity
scores from the estimated competing-risk model.
In this article, we propose to treat unobserved potential outcomes as missing observa-
tions, conducting a model-based analysis by multiply imputing them [38, 40]. The novelty
is in using this method to estimate the causal effect of S2P timing on censored survival
data. Multiple imputation is a straightforward and broadly applicable method that handles
missing or otherwise incomplete observations in a principled way. We adopt it here for
several reasons:
1. It is straightforward to apply in the SVRT example.
2. Unlike a propensity score analysis, it includes all subjects, even those who did not
ultimately undergo S2P.
3. It simplifies analyses for sensitivity to assumptions about which the data are unin-
formative.
4. It correctly accounts for uncertainty about both missing observations and unob-
served potential outcomes [45].
In the next section, we describe the Rubin Causal Model framework and formulate the
needed assumptions and analysis strategy. Specifically, we impute all unobserved post-
S2P survival potential outcomes under a lognormal model. Unlike Westreich et al [53],
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who assumed independence, we can impute the potential outcomes under various as-
sumptions about the correlation of potential outcomes (Section 2.2.2). It is straightforward
to estimate the causal effect of S2P timing on post-S2P survival by directly comparing the
imputed potential outcomes. We then perform a second analysis based on a restricted
cubic spline (RCS) model for the baseline hazard in a proportional hazard model. This
analysis relaxes the strong parametric assumption of the lognormal model. In Section 2.3
we apply our methods to the SVRT data set. In Section 2.4 we offer further discussion.
2.2. Methods
The Rubin causal model [25] takes the potential outcomes for a subject to be the
outcomes that one would observe under the possible levels of a treatment or exposure.
Each potential outcome is a priori observable, in that one could observe it if the unit were
to receive the corresponding treatment, although we ultimately see only the outcome for
the assigned treatment. An approach to the analysis of potential outcomes is therefore
to treat the unobserved outcomes as missing observations and impute their values under
an estimated statistical model. In this way, we can estimate an average causal effect by
averaging the imputed causal effects across the sampled units.
A key hypothesis is the Stable Unit Treatment Value Assumption (SUTVA), which
posits that there is no interference between units and no hidden variation of treatments
among units. “No interference” means that potential outcomes for a given unit do not vary
with the treatments assigned to other units. This seems plausible in our application. “No
hidden variation of treatments” means that there is a single version of each treatment, in
this case the timing of the S2P; this also is plausible.
The fundamental problem of causal inference is the inevitability of missing data; for
each unit, we can observe at most one potential outcome. Thus it is necessary to as-
sume a missingness mechanism — here essentially a treatment assignment mechanism
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— and elucidate its consequences for inferences [37]. For SVRT, we assume that the
unobserved potential outcomes are missing at random (MAR), in the sense that the prob-
ability that a particular potential outcome is unobserved, given observed and missing vari-
ables, depends only on observed variables such as baseline predictors of outcome. That
is, the probability that the subject undergoes S2P at a particular time does not depend
on the survival values at the unselected times, given all observed covariate and outcome
data. MAR is sufficient to justify standard likelihood-based estimation of the model for the
potential outcomes. We make this assumption for both of our imputation models.
Although it is impossible to robustly test the assumption of MAR, one can evaluate
the sensitivity of inferences to departures from it. Imputing data under a plausible non-
ignorable model [20, 50] is a common way to evaluate robustness. If results differ under
alternative assumptions, we can conclude that analyses that flow from an MAR model are
unreliable.
2.2.1. Model-based multiple imputation and analysis
Suppose we have a collection of subjects i = 1, . . . , n who underwent the Norwood
procedure. Among them, n∗ ≤ n later underwent S2P, the rest either dying or receiving a
heart transplant. We observe a q-dimensional baseline covariate vector Xi and an S2P
treatment time Zi ∈ {1, . . . ,Ξ}. For simplicity, we have divided the set of possible S2P
times into six categories: 1–3 months, 4 months, 5 months, 6 months, 7 months, and ≥ 8
months, coded 1–6. With this formulation there are enough patients in each category to
make parametric model estimation feasible. We moreover assume that a notional vector
Ti = (Ti(1), . . . , Ti(6))
T gives the potential outcomes for post-S2P survival under the range
of possible treatments. The realized event time Ti(Zi) may be censored by an observed
censoring time Ci. We let Di be an indicator that equals 1 if subject i is observed to die
after S2P and 0 otherwise, and T ∗i = min (Ti(Zi), Ci) (Table 2.1). Because censoring in
this study is administrative, Ci is independent of treatment assignment and Ti(Zi).
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Table 2.1: Example observations in the SVRT data
Potential Outcomes (days)
Unit Ti(1) Ti(2) Ti(3) Ti(4) Ti(5) Ti(6) Zi Di T ∗i
1 ? ? ? ? ? 1311 6 0 1311
2 ? 1331 ? ? ? ? 2 0 1331
3 ? ? ? 960 ? ? 4 0 960
4 ? ? ? 820 ? ? 4 0 820
5 ? ? 822 ? ? ? 3 0 822
6 ? 690 ? ? ? ? 2 0 690
7 ? ? ? 499 ? ? 4 1 499











2.2.2. A lognormal model
We assume that the log-transformed potential outcome vector lnTi follows the multi-
variate normal distribution
lnTi |Xi;ψ ∼ N (βXi + η,Σ), (2.1)
where ψ represents the model parameters. That is, the mean vector of the distribution is







is a 6-by-q coefficient matrix forXi; and η = (η(1), . . . , η(6))T is a six-vector representing the
causal treatment effects on the log potential outcomes. Thus β(Zi) = (β1(Zi), . . . , βq(Zi))
is the q-vector of covariate effects on the outcome under the realized treatment assign-
ment Zi. We moreover assume that the covariance matrix has diagonal elements Σzz =
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σ2z , z ∈ {1, . . . , 6} and off-diagonal elements σz′z = ρσzσz′ for z′ 6= z ∈ {1, . . . , 6}, with
ρ ∈ [0, 1). Because the likelihood function contains no information on off-diagonal diag-
onal elements of Σ, we set ψ = (β, η, σ21, . . . , σ26), effectively assuming that the potential
outcomes are uncorrelated. We will use imputation to conduct sensitivity analyses under
a range of assumed values of ρ to determine the impact of departures from independence
on final inferences.
Another potential model simplification is to assume that the rows of β are equal —
i.e., that β(z) = β(z′) for z, z′ ∈ {1, . . . , 6} [25]. This is analogous to equal covariate
effects across treatment arms in the analysis of covariance. The data can speak to the
validity of this assumption at the cost of estimating 5q additional parameters, which may
be challenging if the number of observations in any observed treatment arm is modest.
With observed data (x, z, t∗, d), the log-likelihood is








φ(ln t∗i ;µi(zi), σzi)
]
+ (1− di) ln [1− Φ(ln t∗i ;µi(zi), σzi)]
}
,
where t∗i is the observed value of T ∗i ; di is the observed value of Di; and µi(zi) =
β(zi)xi + η(zi). φ(w; ν, τ) is the normal density and Φ(w; ν, τ) the normal distribution func-
tion evaluated at w with mean ν and standard deviation τ .
The first step in the imputation process is to draw M samples from the posterior dis-
tribution of the model parameters p(ψ;x, z, t∗, d). We implement this by approximating
p(ψ;x, z, t∗, d) as N (ψ̂, I−1n∗ (ψ̂)), where ψ̂ is the MLE estimate and In∗(ψ̂) is the observed
information [40, 48]. The next step is to impute missing values given the observed data
and the sampled parameter. There are three scenarios where potential outcomes are
treated as missing:
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1. A patient who does not receive S2P (pre-S2P death or heart transplant): We impute
all six potential outcomes based on baseline covariates Xi.
2. A patient who underwent S2P and was observed to die thereafter: We impute the
logs of the five counterfactual outcomes from their multivariate normal distribution
conditional on the observed log death time.
3. A patient who underwent S2P and whose survival is censored: We sample the log
event time from a truncated marginal survival distribution corresponding to observed
S2P timing zi. Conditional on this imputed event time, we sample the counterfactual
log event times from their multivariate normal distribution given the sampled event
time.
2.2.3. A restricted cubic spline hazard model
Inferences under Model (2.1) may be sensitive to departures from distributional as-
sumptions that will be difficult to detect. An alternative approach is to assume a propor-
tional hazards specification for the outcomes, modeling the baseline hazard as a flexible
parametric function of time. The restricted cubic spline (RCS) model of Herndon et al [21]
satisfies these requirements.
We specify J knots, K1 < K2 < · · · < KJ , with K1 and KJ designated as boundary
knots. We define the restricted cubic spline baseline hazard λ0(u) at post-S2P survival
time u as




where B0(u) = u and, for j = 1, . . . , J − 2,








This differs from the standard cubic spline in having fewer parameters and being con-
strained to be linear beyond the boundary knots.








exp (γTxi + κ(zi)), (2.2)
where αj is the coefficient for the restricted cubic spline; xi is the covariate vector for
subject i; zi is the assigned treatment; γ is a vector of covariate effects; and κ is a vector
of potential hazard factors. We denote the parameter of Model 2.2 as χ = (α, γ, κ). With
implicit conditioning on the parameter and covariate vector, the survival function Si(u, zi)
is then








We impute incomplete observations under Model (2.2) by the Bayesian bootstrap [39].
To create the m-th imputed data set, we perform the following steps:
1. Sample a uniform Dirichlet deviate with the same dimension as the number of rows
in the dataset.
2. Using the Dirichlet components as weights, sample a data set from the raw data
with replacement.
3. Obtain χ̂(m) = (α̂(m), γ̂(m), κ̂(m)) by estimating Model (2.2) using the data from step
(2).
4. Using the inverse-CDF transformation, impute the unobserved potential post-S2P
survival outcomes T (m)i (z), z 6= zi, independently from their distribution conditional
on the data and the sampled parameters.
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Step (4) involves creation of the completed data given observed data and the sampled
parameter estimate. For completely unobserved outcomes, one samples from the survival
function in Equation (2.3). For censored outcomes for the observed Zi, one samples from
the survival function restricted to lie beyond Ti. All sampling of completed observations
assumes independence of potential outcomes.
2.2.4. Inference on the causal parameter
Under both statistical models, the imputed potential outcomes T (m)i are the potential
post-S2P survival days. For simplicity, take the S2P procedure to be successful when the
imputed post-S2P survival is longer than 10 years; that is, the parameter of interest is the
proportion of imputed post-S2P survival times exceeding 10 years for each treatment z.
Denote this vector θ(z), and assume that its variance-covariance matrix from a complete
data set is V . Denote the estimate and variance from the m-th imputed data set as θ̂(m)
and V (m), respectively. Then one can create inferences about θ using the well-known
Rubin combining formulas [40, 42].
We estimate the optimal S2P timing from the plot of θ̂(z) against z with 95% confidence
intervals. To construct a confidence interval for optimal S2P timing when using multiple
imputation, we apply the method “Bootstrap+MI” of Schomaker et al [43]. This method
involves creation first of a bootstrap sample of the data followed by a multiply imputed
sample.
2.2.5. Computing
We created imputations in R 3.5.2 and analyzed them in SAS 9.4 using PROC MIAN-
ALYZE.
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2.3. Application to the SVRT Data
2.3.1. The Single Ventricle Reconstruction Trial
The Pediatric Heart Network conducted the SVRT at 15 centers from 2005 to 2009;
study data are available at http://www.pediatricheartnetwork.com. The primary goal of
SVRT was to evaluate the effect of the type of Norwood procedure (stage 1 treatment)
on one-year transplant-free survival of newborns with hypoplastic left heart syndrome
(HLHS). The trial randomized newborns to undergo either a modified Blalock-Taussig
shunt (MBTS) or a right ventricle-to-pulmonary artery (RVPA) shunt. Survivors would
undergo S2P at a time determined by the surgical team, typically several months after the
Norwood operation. Ohye et al [30] give more details on the study design and the data.
Figure 2.1: Treatment and outcome patterns in the SRVT data
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The data set contains baseline variables, information on the Norwood and S2P oper-
ations, and survival time. Among 548 randomized HLHS patients who had operative data
and follow-up, 139 died prior to S2P, and 9 received a heart transplant. The remaining
400 underwent S2P (Figure 2.1).
Roughly 60% of the infants were male, and 80% were white. Newborns in the RVPA
arm were more likely to undergo S2P. Subjects who underwent S2P were heavier at birth
and slightly younger at the time of the Norwood procedure and post-Norwood discharge,
compared with the subgroup who died or underwent cardiac transplantation without S2P.
2.3.2. Analysis under the lognormal model
Using the Akaike information criterion (AIC), we selected a panel of predictive co-
variates including sex, race, randomized Norwood procedure (MBTS vs. RVPA), prenatal
diagnosis of congenital heart disease, aortic atresia, obstructed pulmonary venous return,
birth weight, age at Norwood, and age at Norwood discharge.
We conducted a sensitivity analysis to determine whether assumptions about the cor-
relation of the potential outcomes would influence final causal inferences. Assuming a
homogeneous compound symmetry model (σ21 = . . . = σ26), we imputed data under the
lognormal model separately for common correlation values ρ ∈ {0, 0.3, 0.6, 0.9}. Figure 2.2
shows that there is minimal sensitivity to the assumed value of ρ.
Figure 2.3 shows results from M = 200 imputations under the lognormal model with
varying common correlation coefficient. The peak fraction surviving occurs at the S2P
time 6 months after Norwood under all four models. The proportion of imputed post-S2P
survival times greater than 10 years ranges from 0.68 to 0.84 (Table 2.2).
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Table 2.2: Parameter estimates using the lognormal model (M = 200)
Correlation Standard 95% Confidence Interval
Coefficient Parameter Estimate Error Lower Limit Upper Limit
ρ = 0 θ(1) 0.683 0.025 0.634 0.731
θ(2) 0.702 0.024 0.654 0.749
θ(3) 0.792 0.020 0.753 0.830
θ(4) 0.832 0.018 0.798 0.867
θ(5) 0.815 0.020 0.775 0.855
θ(6) 0.784 0.021 0.743 0.825
ρ = 0.3 θ(1) 0.676 0.024 0.627 0.724
θ(2) 0.707 0.024 0.660 0.755
θ(3) 0.794 0.019 0.755 0.832
θ(4) 0.838 0.017 0.803 0.873
θ(5) 0.816 0.020 0.776 0.857
θ(6) 0.778 0.020 0.737 0.818
ρ = 0.6 θ(1) 0.667 0.024 0.619 0.716
θ(2) 0.697 0.023 0.650 0.744
θ(3) 0.784 0.019 0.745 0.823
θ(4) 0.831 0.017 0.797 0.866
θ(5) 0.814 0.020 0.774 0.854
θ(6) 0.781 0.020 0.740 0.821
ρ = 0.9 θ(1) 0.675 0.024 0.628 0.723
θ(2) 0.690 0.023 0.642 0.737
θ(3) 0.784 0.019 0.745 0.822
θ(4) 0.835 0.017 0.801 0.869
θ(5) 0.808 0.020 0.768 0.849
θ(6) 0.781 0.020 0.741 0.822
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Figure 2.2: Inference on the causal parameter as a function of the common correlation ρ
in the lognormal model (M = 200)
The results above assume equal covariate effects across treatment arms; that is,
β(z) = β(z′) for z, z′ ∈ {1, . . . , 6}. A larger data set would allow us to estimate a sep-
arate covariate effect in each arm. In addition, a homogeneous compound symmetry
model (σ21 = . . . = σ26) simplifies the likelihood function, rendering the optimization more
stable and likely to converge. We conducted an analysis assuming non-homogeneous
error variance (not shown), which yielded the same overall results.
2.3.3. Analysis under the RCS model
Estimates of θ imputed under the RCS model appear in Table 2.3 and Figure 2.4.
After a grid search using AIC as fit criterion, we set knots at 700 and 1400 days post-
S2P survival. We then applied multiple imputation with M = 20, 100, 200 and 500.
Table 2.3 shows that the proportion of imputed survival times greater than 10 years for
z = 1, . . . , 6 are roughly 0.77, 0.81, 0.87, 0.91, 0.88 and 0.86, regardless of M , with
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Figure 2.3: Confidence intervals on the causal parameter as a function of the common
correlation ρ in the lognormal model (M = 200)
estimates stabilizing by M = 200. Although θ values are generally higher than under the
lognormal model, the ranking of θ(z) is the same. We identify the optimal S2P timing as
6 months after the Norwood procedure.
To obtain a 95% confidence interval for the optimal S2P timing, we drew 100 bootstrap
samples, performing the MI procedure M = 20 times within each. In the 100 bootstrap
samples, the best S2P time was 6 months 82 times, 7 months 8 times, and ≥ 8 months 6
times (Figure 2.5). Thus, a bootstrap 95% confidence interval for optimal S2P timing is 6
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Figure 2.4: Inference on the causal parameter as a function of the number of imputations
in the restricted cubic spline model
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Table 2.3: Parameter estimates using the RCS model
Standard 95% Confidence Interval
M Parameter Estimate Error Lower Limit Upper Limit
20 θ(1) 0.768 0.024 0.721 0.815
θ(2) 0.811 0.021 0.768 0.852
θ(3) 0.869 0.020 0.829 0.909
θ(4) 0.906 0.014 0.878 0.932
θ(5) 0.881 0.019 0.842 0.919
θ(6) 0.862 0.018 0.825 0.897
100 θ(1) 0.770 0.026 0.726 0.815
θ(2) 0.813 0.021 0.771 0.854
θ(3) 0.871 0.018 0.836 0.905
θ(4) 0.906 0.014 0.878 0.934
θ(5) 0.880 0.018 0.844 0.915
θ(6) 0.862 0.018 0.827 0.897
200 θ(1) 0.771 0.022 0.727 0.815
θ(2) 0.813 0.020 0.774 0.853
θ(3) 0.870 0.017 0.838 0.903
θ(4) 0.906 0.014 0.878 0.934
θ(5) 0.879 0.018 0.844 0.915
θ(6) 0.862 0.018 0.827 0.897
500 θ(1) 0.771 0.022 0.727 0.814
θ(2) 0.814 0.020 0.775 0.853
θ(3) 0.870 0.017 0.837 0.905
θ(4) 0.905 0.015 0.876 0.935
θ(5) 0.879 0.018 0.845 0.914
θ(6) 0.861 0.018 0.826 0.879
to infinity.
In the SVRT data, most patients have pre-S2P events (death or heart transplantation)
or are censored within 3 years of S2P. One patient, however, is purported to have a post-
S2P censoring time of 2,704 days, or 7.4 years. This is a possibly influential outlier. The
non-parametric RCS model is more responsive to this point, potentially explaining the
generally higher values of θ under this model. The parametric lognormal model gives a
slightly lower fitted survival probability in the tail of the survival curve.
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Figure 2.5: Count of optimal S2P timing from 100 times bootstrap (M = 20)
2.3.4. Testing linear hypotheses for the parameters
To determine the causal effect of S2P timing on θ, we tested linear contrasts of the
θ(z) terms. Results under the RCS model appear in Table 2.4. The only significant
contrast is θ(3) − θ(2) with estimate 0.06 (M = 200) and 95% confidence interval 0.01–
0.11. This means having S2P at 5 months after Norwood procedure is significantly better
than having S2P at 4 months. The conclusion is insensitive to the number of imputations.
Under the lognormal model, we find same single significant contrast, and the conclusion
is insensitive to the correlation coefficient ρ.
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Table 2.4: Causal contrasts of θ terms
95% Confidence Interval
M Parameter Estimate Lower Limit Upper Limit
20 θ(2)− θ(1) 0.042 −0.020 0.104
θ(3)− θ(2) 0.059 0.009 0.109
θ(4)− θ(3) 0.036 −0.013 0.086
θ(5)− θ(4) −0.025 −0.073 0.024
θ(6)− θ(5) −0.019 −0.074 0.035
100 θ(2)− θ(1) 0.042 −0.017 0.101
θ(3)− θ(2) 0.058 0.008 0.108
θ(4)− θ(3) 0.035 −0.009 0.081
θ(5)− θ(4) −0.026 −0.072 0.019
θ(6)− θ(5) −0.018 −0.068 0.032
200 θ(2)− θ(1) 0.042 −0.016 0.100
θ(3)− θ(2) 0.057 0.008 0.107
θ(4)− θ(3) 0.035 −0.008 0.080
θ(5)− θ(4) −0.027 −0.071 0.018
θ(6)− θ(5) −0.018 −0.068 0.032
500 θ(2)− θ(1) 0.042 −0.015 0.099
θ(3)− θ(2) 0.057 0.007 0.107
θ(4)− θ(3) 0.035 −0.008 0.080
θ(5)− θ(4) −0.027 −0.071 0.018
θ(6)− θ(5) −0.018 −0.068 0.032
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2.4. Discussion
We have proposed a multiple imputation strategy to create causal inferences for the
effect of S2P timing on survival outcomes in infants with HLHS. Imputation under a log-
normal model showed that inferences are insensitive to the assumed, and inestimable,
correlation of potential outcomes. A more flexible cubic spline hazard model gave esti-
mates that were generally larger for the fraction surviving 10 years, although causal con-
trasts between z values were similar to those from the lognormal. Both sets of analyses
suggest that the optimal S2P time occurs at 6 months.
Imbens and Rubin [25], working in the context of continuous, non-censored outcomes,
observed that causal inferences are generally insensitive to the assumed value of the in-
estimable correlation coefficient of the potential outcomes. Our sensitivity analysis under
the lognormal model gave a similar result. Our RCS model assumes independence of the
potential outcomes given the covariates; it is unclear whether these inferences are also
insensitive.
In medical practice, the dynamic variable pulmonary vascular resistance (PVR), a bio-
marker of the maturity of the infant’s circulatory system, is a key determinant of the timing
of S2P. A limitation of this study is that the data contain only a baseline PVR measurement,
which is absent in roughly half of the data. Therefore, we were unable to include PVR in
our analysis.
In a previous study [4], we used inverse propensity score weighting to eliminate con-
founding bias in estimation of the causal effects of S2P timing on survival in the SVRT
data. The key ignorability assumption in that analysis was weak unconfoundedness
[23, 57]. Our analyses necessarily excluded the 148 newborns who died or underwent
heart transplantation (and therefore did not undergo S2P). The analysis in this article in-
cludes those subjects, as they are assumed to have the full vector of potential outcomes
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even if we do not know their Zi values.
By constructing M completed datasets and properly combining inferences based on
them, one can eliminate bias due to systematic differences between the observed and
unobserved data [2]. Multiple imputation also offers a straightforward path to sensitivity
analysis through the incorporation of non-ignorable features into imputation models [41].
In conclusion, the optimal timing of S2P is roughly 6 months after Norwood procedure
with a 95% confidence interval of 6 to infinity. This result is consistent with the previ-
ous analysis that we conducted that created propensity scores using a competing-risks
analysis and estimated hazard ratios using inverse propensity score weighting [4].
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CHAPTER 3
Developing a VA Women’s Cardiovascular Disease Risk Score
3.1. Introduction
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and
disability in North America and the third-leading cause of death in women veterans [52].
Women military service members and veterans have significantly higher numbers of car-
diovascular risk factors and poorer health status than their civilian counterparts [16, 27].
Previous studies [3, 51] report that women service members have almost twice the bur-
den of traditional cardiovascular disease (CVD) risk factors, such as hypertension, at
younger ages (< 40 years) than their civilian counterparts. Currently, women enlistees
are significantly younger than male enlistees in the military, and military exposure earlier
in life may alter the aging trajectory on ASCVD risk factors [54]. Therefore, aging-related
changes in ASCVD risk factors among Veterans Affairs (VA) women may differ from those
experienced by their civilian counterparts.
The current DoD (Department of Defense)/VA guidelines for cardiovascular disease
screening and treatment of hypertension and hypercholesterolemia rely on the American
College of Cardiology/American Heart Association (ACC/AHA) ASCVD risk assessment
model. The ACC/AHA model was developed from Goff et al [13] based on a pooled
epidemiologic dataset containing civilian men and women aged 40 to 79 years old. Con-
sistent with this, the current DoD/VA guideline recommends screening women for ASCVD
risk starting at age 45 [33]. But because the traumatic stress associated with military
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service earlier in life may alter the aging effect on ASCVD risk factors [9], it is unclear that
the current screening strategy is adequate for VA women.
VA women differ from women in the general population not only in prevalence of tradi-
tional and non-traditional CVD risk factors [16], but also in racial and ethnic group repre-
sentation. To examine whether the current ACC/AHA ASCVD model is applicable to VA
women, we re-estimated VA women’s ASCVD risk using the VA national Electronic Health
Records (EHR) database, which includes younger women service members aged 30–39,
similarly to the current ACC/AHA models [5]. This database is the largest longitudinal
health record in the U.S. health care system and the best data available on the VA women
population. Our analysis identified a curvilinear association of aging with ASCVD risk in
VA women starting at ages as young as 30 years across all races. This differs substan-
tially from the previous consensus, which was that women face minimal ASCVD risk until
age 45. Our observation suggests a need for cardiovascular risk screening of VA women
at ages less than 45, and the development of a new validated CVD risk model adequately
assessing CVD risk for VA women.
We aim to develop a new CVD risk model for VA women using the VA national EHR
database. To improve prediction accuracy (or calibration) and precision (or discrimination)
of the new CVD model, the study incorporated all available visit data and aging-related
changes in CVD risk factors. Using information from multiple visits, we have developed the
VA Women CVD Risk Score, based on a parsimonious predictive model and calculated
using time-dependent covariate Cox regression [7].
3.2. Study Cohort and Data Preparation
The study cohort is defined by women veterans aged were between 30 and 79 years
and alive on January 1, 2007 with at least one outpatient or inpatient visit diagnosis.
92,682 VA women with records in the VA Corporate Data Warehouse (CDW) met these
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criteria. Of these, we excluded 14,126 women who were missing data on baseline co-
variates, e.g., blood pressure and lipids. Because we focused on inference for white,
African American, and Hispanic patients, we excluded a further 8,982 VA women of other
races. We were left with data on 69,574 women service members and veterans: 36,172
non-Hispanic whites (52%), 29,231 non-Hispanic African Americans (42%), and 4,171
Hispanics (6%). See Figure 3.1.
We extracted data using the Structured Query Language (SQL) Server Management
Studio (SSMS, Version 2017, Microsoft Corp., Redmond, WA) and conducted statistical
and graphical analyses using SAS Enterprise Guide (version 7.1, SAS Institute, Cary,
NC) and R (Version 3.5.3, cran.r-project.org). We performed all data extraction, prepara-
tion, and analyses within the domain of the VA Informatics and Computing Infrastructure
(VINCI). Death event and cause of death data are obtained from the VINCI Vital Sta-
tus File, which compiles data from the BIRLS (Beneficiary Identification Records Locator
Subsystem), the VA Medicare Vital Status File, and the National Death Index (NDI) for
Veterans, which is a part of the VA Suicide Data Repository (SDR). All variables of in-
terest in the current study are extracted from VA national EHR data, situated in the VA
national Corporate Data Warehouse (CDW). The CDW data contain health records of all
patients treated in the VA Health Care System.
We transformed the data to represent values in six-month equal-length windows, with
data considered to be missing when there are no visit records in the window. Specifically,
the first interval (denoted the baseline visit) runs from January 1, 2007 to June 30, 2007.
Subsequent intervals run from July 1, 2007 to December 31 2007, January 1, 2008 to
June 30, 2008, etc. There are 22 intervals in total. If there is no visit within the first
interval, the first following available visit is set as the baseline. We consider each interval
to contain one record per patient; if a patient has multiple visits in a window, we represent
risk factor data as the average across the visits for continuous variables (e.g. HDL) or
maximum for binary variables (e.g. diabetes, current smoking status).
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Figure 3.1: Data extraction process
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Because of the sensitive nature of the Veterans Affairs (VA) data collected for this
study, access is restricted to VA-affiliated researchers trained in human subject confi-
dentiality protocols. Requests may be sent to the VA North Texas Health Care System
Institutional Review Board (IRB) at NTXIRBAdmin@va.gov.
3.3. Method
3.3.1. Re–estimating the ACC/AHA model
The ACC and AHA seek to improve the prevention, detection, and treatment of car-
diovascular disease (CVD) through the promulgation of guidelines. The Goff [13] CVD
risk assessment tool, based on the Cox proportional hazards model, is the basis of the
current ACC/AHA risk assessment guideline.
As mentioned above, the Goff model applies to civilians aged 40–79 years with no pre-
vious history of nonfatal myocardial infarction (recognized or unrecognized), stroke, heart
failure, percutaneous coronary intervention, coronary artery bypass surgery, or atrial fib-
rillation.
The Goff model evaluates risk separately for whites and American Africans. The
model for whites includes age, age squared, untreated systolic blood pressure (SBP),
treated SBP, current smoking status, diabetes, total cholesterol, high-density lipoprotein
(HDL), and several interaction terms: current smoking status*age, total cholesterol*age,
and HDL*age. The African American model omits the age squared term and smoking*age
and total cholesterol*age interactions, while including the SBP*age interaction. All contin-
uous predictors in these models appear on the log scale.
We re-estimated the Goff model using our VA EHR data and evaluated it by C-statistics
and calibration plots. Because this model cannot handle time-varying covariates, we used
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only predictors measured at the baseline visit. The ACC/AHA model estimates sepa-
rate coefficients for white women and African American women, and excludes Hispanic
women. We applied both the white and African American ACC/AHA models to Hispanic
women to estimate their ten-year ASCVD risk.
We assume that each of n subjects, labelled i = 1, . . . , n, has a p-dimensional predictor
Xi of biomarkers and risk factors. Let Ti stand for the CVD event time for subject i, and
assume that it is potentially censored at time Ci. The observed event/censoring time is
T ∗i = min(Ti, Ci), with the indicator ∆i equal to 1 if T ∗i is an event time and 0 if T ∗i is a
censoring time.
We let λ∗i (t|X) refer to the ASCVD event hazard function for subject i. The Cox pro-
portional hazards model takes the following form:







where λ∗0(t) is the baseline hazard at time t, and βj is the coefficient for the j th risk fac-
tor. We interpret exp(βj) as the hazard ratio (HR) resulting from a one-unit increase in
predictor j. We note here two facts about the model:
1. The baseline hazard λ∗0(t) depends on t, but not on Xi.
2. The hazard ratio exp(βXi) depends on Xi but not on time t.
3.3.2. VA Women Cardiovascular Disease Risk Score
In our VA EHR database, patients have multiple visit records, with measured values
of the risk factors potentially varying across visits. Thus we can represent the risk factor
vector Xi as a function of time: Xi(t) is the vector of risk factors for subject i, measured at
time t. With this representation we can apply a more general form of the Cox model that
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allows the hazard to vary over time in response to changes in the predictors. We define
the time-dependent covariates Cox proportional hazard model as







where λ0(t) is the baseline hazard at time t, and the hazard λi(t|Xi(t)) for subject i at time
t depends on the value of the risk factor vector at time t.
We constructed ASCVD risk factors from VA EHR data following Sussman et al [46],
and ASCVD events (non-fatal myocardial infarction, non-fatal stroke, and cardiac death)
using ICD-9 and ICD-10 diagnostic and procedural codes from VA national EHR data
and the NDI data. We validated myocardial infarction and stroke events by searching for
words such as “MI”, “myocardial infarction”, and “stroke”, respectively, embedded in health
providers’ narratives and notes extracted from VA EHR.
After building the model, we used the Harrell C-statistic [17, 18] to evaluate its preci-
sion and ability to discriminate ASCVD events. We also used calibration plots to evaluate
the quality of the prediction model.
The calibration plot compares the predicted probability with the observed probability.
Under an ideal model, pairs of observed and predicted probabilities would lie on the 45-
degree line, meaning that they agree exactly. We describe here the process of obtaining
the calibration plot for the time-dependent covariate Cox model:
1. Randomly split the original data into training and test data sets in the ratio 4:1. That
is, we sample 80% of unique patient IDs without replacement and use them as the
training set, with the remaining 20% representing the test set.
2. Estimate the proposed time-varying Cox model using the training set; obtain the
predicted 10-year ASCVD risk by plugging in the covariate values from the test set;
the final predicted risk is the average risk over all patients in the test set.
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3. Calculate the observed risk as one minus the Kaplan-Meier (KM) survival estimate
at 10 years.
We repeat steps (1)–(3) 100 times to get 100 pairs of predicted and observed risk.
The final calibration plot, with a 45–degree straight line as the reference, is the line plot
connecting the above 100 dots (x-axis: predicted risk; y-axis: observed risk) after sorting
the data.
3.4. Results
3.4.1. The VA EHR data
Table 3.1 shows that the study cohort consisted of 69,574 women: 52% white with
mean age 46; 42% African American with mean age 44; and 6% Hispanic with mean age
43. Patients under 40 constitute 16% of the sample. African American women have the
highest mean SBP and HDL cholesterol, but lowest mean total cholesterol. They also
have the highest prevalence of diabetes and the lowest of current smoking.
The enrolled women experienced 2,176 deaths from any cause (3.1%); of the women
who died 1,321 were white (1.9%); 781 were African American (1.1%); and 74 were His-
panic (0.1%). Table 3.2 describes ASCVD events by race and type. Non-fatal myocardial
infarction is the most common ASCVD event, followed by non-fatal stroke and cardiac
death. The rate of stroke is significantly higher in African American women (2.0%) than in
white women (1.5%).
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Table 3.1: Baseline risk factors stratified by race and ethnic group.
White African American Hispanic
n = 36, 172(52%) n = 29, 231(42%) n = 4, 171(6%)
Continuousa
Age (year) 45.9(8.7) 44.2(7.8) 43.1(8.4)
Systolic blood pressure (mmHg) 123.8(14.8) 127.1(15.8) 122.2(14.6)
Total cholesterol (mg/dL) 200.0(40.8) 192.4(38.9) 195.6(38.3)
High-density lipoprotein (mg/dL) 53.8(16.7) 56.9(17.4) 53.83(15.6)
Discrete
Diabetes 8,405(23.2%) 9,569(32.7%) 1,056(25.3%)
Current smoking 10,864(30.3%) 5,111(17.5%) 994(23.8%)
aValues given as mean(SD)
Table 3.2: ASCVD events stratified by race and ethnic group
ASCVD type White African American Hispanic
Non-fatal myocardial infarction (MI) 1,515 1,148 148
Non-fatal stroke 538 592 61
Cardiac death 245 144 16
Heart failure 175 151 18
Cardiac arrest 9 6 2
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3.4.2. Re–estimating the ACC/AHA model
We re-estimated the ACC/AHA model using the VA EHR data with patients younger
than 40 years old. Figure 3.2 plots the covariate-adjusted aging effect. We can see that
the estimated 10-year ASCVD risk for VA women increases curvilinearly with older age,
starting at age 30.
The Figure 3.2 (a) displays the aging effect on 10-year risk of ASCVD event for whites
(solid line) and African Americans (dotted line). Both of the predicted 10-year risk of
ASCVD event are about 5% at age 30 years old. That risk of white veteran increases
slowly and surpasses that of African American at age 55. It reaches around 15% at age
79, comparing with 8% for African American veteran. Since Goff et al [13] only have the
models for white or African American veteran, we apply both of the two models for the
Hispanic veteran VA women in our dataset. The result shows in Figure 3.2 (b) having
similar pattern as Figure 3.2 (a).
3.4.3. VA women Cardiovascular Disease Risk Score
Goff et al [13] proposed separate time-independent covariate models for white and
African American civilians. To simplify prediction, we have built a single, parsimonious
model that is valid for all three race/ethnic groups. The risk factors are age, untreated
systolic blood pressure, treated systolic blood pressure, diabetes mellitus status (yes or
no), current smoking status (yes or no), major depression (yes or no), total cholesterol,
HDL, and antihypertensive treatment (yes or no). Unlike Goff’s models, ours contain no
interaction terms.
We have created two separate models: Model 1 predicts any of non-fatal myocardial
infarction (MI), non-fatal stroke, and cardiovascular death; and Model 2 predicts these
outcomes plus heart failure and cardiac arrest. Both models include all of the predictors
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Figure 3.2: Estimated effect of aging on increased 10-year ASCVD risk, stratified by race
for women military service members: (a) whites (solid line) and African Americans (dotted
line); (b) Hispanic veterans by the models for white and African Americans.
indicated above. The coefficients of the ASCVD risk factors, interpreted as log hazard
ratios, appear in Table 3.3, stratified by race. Table 3.3 shows that model 1 and model 2
typically have similar coefficient values. A positive (negative) coefficient means that the
risk factor has a positive (negative) correlation with the ASCVD risk. In all race/ethnic
groups, high ASCVD risk is associated with older age, higher SBP and total cholesterol
level, lower HDL, and presence of smoking, diabetes, and major depression.
Baseline survival probabilities for the Model 1 events at 10 years, estimated from the
Kaplan-Meier curve, are 0.944, 0.944, and 0.954 for whites, African Americans, and His-
panics, respectively. These probabilities are slightly lower after adding heart failure and
cardiac arrest as outcome events (as in Model 2). We calculated the predicted 10-year
ASCVD risks using the two outcome models for all race groups, fixeing the covariates as
age 38, total cholesterol 199 mg/dL, HDL 50 mg/dL, systolic BP 138mmHg, no diabetes,
no major depression, no current smoking and no antihypertensive treatment. These re-
sults appear as the final row in Table 3.3, where we see that African American women
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Table 3.3: Time dependent Cox PH model estimates
White African American Hispanic
Model 1a 2b 1 2 1 2
Age 2.399 2.493 2.058 2.074 2.191 2.291
Untreated hypertension 1.008 1.018 0.411 0.526 0.653 0.812
Treated hypertension −0.208 0.463 1.246 1.664 −3.714 −1.391
Diabetes mellitus 0.425 0.457 0.276 0.350 0.315 0.301
Current smoking 0.072 0.073 -0.020 -0.004 0.356 0.413
Major depression 0.244 0.254 0.231 0.282 0.311 0.393
Total cholesterol 0.024 0.167 0.180 0.096 0.099 0.107
High-density lipoprotein −1.350 −1.295 −1.339 −1.276 −1.225 −1.208
Antihypertensive treatment 1.263 −1.966 −5.795 −7.698 18.290 7.061
C-statistic 0.700 0.710 0.680 0.683 0.660 0.671
S(10)c 0.944 0.939 0.944 0.939 0.954 0.949
10-year CVD risk (%)d 4.070 4.340 4.970 5.200 3.810 4.220
aOutcome is MI + stroke + cardiovascular death
bOutcome is MI + stroke + cardiovascular death + heart failure + cardiac arrest
c10-year CVD event free survival probability
d1-S(10)exp(β̂X−β̂X̄), where X is a vector of covariates, X̄ is the mean value of the corre-
sponding covariates, and β̂ is the vector of estimated regression coefficients (log hazard ratios).
Specific values used in the table are age 38 years, total cholesterol 199 mg/dL, HDL 50 mg/dL,
SBP 138 mmHg, no diabetes, no major depression and no current smoking status.
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have the highest predicted risk at nearly 5%.
The performance of our VA women risk score is evaluated by C-statistics and predic-
tion accuracy (calibration plot). All C-statistics for our models are around 0.7; thus they
are uniformly better than the ACC/AHA models in Section 3.3.1, which give C-statistics
slightly over 0.6. A C-statistics of 0.7 generally is interpreted to represent good prediction
precision.
Figure 3.3 displays calibration plots for Model 1 by race group. For white women,
Model 1 overestimates the 10-year ASCVD risk slightly when the observed risk is lower
than 0.1, and underestimates risk when the observed risk greater than 0.1. As the cali-
bration plot is roughly centered around the 45-degree line, this discrepancy is considered
acceptable. The calibration plots for African American and Hispanic women reveal similar
patterns. Calibration plots for the model 2 outcome (Appendix Figure C.1) have similar
appearance.
To evaluate the prediction discrepancy between our risk score and the ACC/AHA
model, we calculated the 10-year predicted ASCVD risk for each subject in our VA EHR
database using these models (Table 3.4). For simplicity, we classify estimated ASCVD risk
as either low (< 7.5%), moderate (7.5–19.9%), or high (≥ 20%) [15]. Because ACC/AHA
models only apply to whites and African Americans, we omit Hispanics from the compar-
ison. As Table 3.4 shows, our risk score classifies white women who are at low risk by
ACC/AHA into moderate (n = 6 962) or high-risk groups (n = 3 763). For African Ameri-
cans, our model predicts 4,531 women in the low risk category whom the ACC/AHA model
marks as of moderate risk. Most of the re-classifications are nevertheless consistent.
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Figure 3.3: Calibration plots for VA women ASCVD risk model 1 by race
Table 3.4: Comparison of model prediction between VA women
risk score and ACC/AHA model
VA women ASCVD risk score
< 7.5% 7.5%− 19.9% ≥ 20%
< 7.5% 19,572(20,185)a 6,962(1,485) 3,763(0)
ACC/AHA model 7.5%− 19.9% 50(4,531) 3,108(2,828) 2,636(147)
≥ 20% 0(46) 0(0) 80(9)
aValues given are for whites (African Americans)
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3.5. Discussion
We have proposed a new 10-year ASCVD risk prediction model for Veterans Affairs
women based on data from the VA national EHR database. We evaluated the new model
by C-statistics, calibration plots, and reclassification performance when compared with
the current ACC/AHA CVD risk model [13]. In predicting risk for VA women, our new
model is more accurate, precise, parsimonious, and stable than the ACC/AHA model.
Our proposed ASCVD risk score includes the traditional CVD risk factors: age, SBP,
diabetes, current smoking status, total cholesterol, and HDL. We have also identified a
new risk factor — major depression — that leads to statistically significant improvement
in ASCVD risk prediction.
Our study has substantial strengths:
1. It is based on the VA national EHR database with a sample size of more than 90,000;
therefore it is representative of the VA women population and stable.
2. The proportion of minority women is moderate, making the model reliable for differ-
ent race groups.
3. The VA national EHR data, unlike other non-VA EHR databases, is able to follow
patients over substantial periods of time. This longitudinal (multiple visits) feature
allows us to build a Cox PH model that has time-dependent predictors and is there-
fore potentially more accurate.
4. The database includes a substantial number of VA women under age 40, improving
the credibility of the model for predicting ASCVD risk in this young but susceptible
population.
5. Provider narrative notes (medical notes) in the database enable us to verify the
outcome events, like non-fatal MI, non-fatal stroke, etc., identified through their ICD
codes.
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EHR data are often criticized for containing mis-classified ICD-9 and ICD-10 codes.
For example, some studies have found inaccruate ICD diagnosis codes for stroke events,
with concordance of only 50%–61% with providers’ note [14, 32]. In our database, the
concordance between ICD codes and medical note is 92.5% for non-fatal stroke and
96.9% for non-fatal MI. ASCVD events derived from ICD codes are therefore reliable in
the VA EHR database.
Our analysis has several limitations:
1. Our model cannot incorporate information about menopause or history of other
pregnancy-related conditions/complications. Future work could incorporate these
female-specific biomarkers.
2. Our analysis assumes non-informative censoring, in the sense that loss to follow
up is statistically independent of the time to the ASCVD event. Violation of this
assumption could bias estimates. This would occur if, for example, patients suffering
stroke or MI are more likely to visit the nearest hospital rather than their regular
VA hospital, and in that case our model would underestimate ASCVD risk. Future
studies could assess the sensitivity of results to violation of this assumption.
3. The current study is limited to VA women with complete data on vital signs, SBP,
total cholesterol and HDL at baseline visits. If women who do not have all of these
variables available differ from those who do with respect to risk factors for ASCVD,
some bias may result.
4. VA women younger than age 30 and older than 80, and smaller minority groups
such as Asians are not included in the current study cohort.
In summary, we have proposed an accurate and parsimonious 10-year ASCVD risk
prediction model that performs better in VA women than the current ACC/AHA guideline
model. It is a consistent risk score that fits the three major race/ethnic groups of VA
women and demonstrates a new aging effect on ASCVD risk. Because the number of
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women in the U.S. military has increased rapidly in recent years [1], a precise and usable
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A.1.
Figure A.1: Histogram of S2P times of 400 patients who underwent S2P, by elective status
of the procedure
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Figure A.2: Estimated one-year survival probability after S2P, estimated by the method of
Hu et al. (2018)
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Figure A.3: Average probability of the three competing events — elective S2P, non-
elective S2P, and death/cardiac transplantion — over time
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Figure A.4: Log mortality hazard ratio as a function of S2P timing: (a) Elective S2P only;
(b) non-elective S2P only.
Figure A.5 presents the log hazard ratio as a function of time from Norwood to S2P
(Z) estimated under three models: Unsmoothed, using discrete Z (shown in red, with a
triangle at the estimate); smoothed by a linear spline, with discrete Z (black, circle); and
smoothed using a linear spline with continuous Z (blue, star). Both discrete-Z methods
give a minimum hazard ratio at Z = 6, and the continuous-Z method gives a minimum
hazard at Z = 6 (with knots chosen at integer Z). Estimated hazard ratios are similar at
all times. Standard errors for the analysis with continuous Z are often less than those with
discrete Z.
Figure A.6 presents the log hazard ratio as a function of time from Norwood to S2P
(Z) estimated under the three models, now stratified by elective status of the S2P. The
models are coded as in Figure A.5. The discrete-Z methods give nearly identical results.
The continuous-Z method gives similar results with smaller standard errors but is sensitive
to the choice of knots in the spline function.
In the survival models with continuous Z we used weights estimated from the discrete-
Z competing-risk model. We also removed one patient who had an outlying S2P time (23
months; see Figure A.1). We selected a final model by the Akaike information criterion,
starting from a family of models with knots at the discrete Z values.
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Figure A.5: Log mortality hazard ratio as a function of S2P timing, estimated under three
models using all S2P patients
Figure A.6: Log mortality hazard ratio as a function of S2P timing, estimated under three
models and stratified by elective S2P status: (a) Elective S2P; (b) non-elective S2P.
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A.2.
Table A.1: Descriptive statistics by S2P time (in months)
Variables 1–3 (n=30) 4 (n=69) 5 (n=103) 6 (n=105) 7 (n=44) ≥8 (n=49)
Z = 1 Z = 2 Z = 3 Z = 4 Z = 5 Z = 6
Discrete
Sex M 21(70%) 45(65%) 64(62%) 68(65%) 25(57%) 29(59%)
F 9(30%) 24(35%) 39(38%) 37(35%) 19(43%) 20(41%)
Race White 28(94%) 61(88%) 83(80%) 83(79%) 32(72%) 36(73%)
Black 1(3%) 5(7%) 15(15%) 16(15%) 10(23%) 12(24%)
Other 1(3%) 3(5%) 5(5%) 6(6%) 2(5%) 1(3%)
Norwood arm MBTS 18(60%) 17(25%) 49(48%) 54(51%) 16(36%) 23(47%)
RVPA 12(40%) 52(75%) 54(52%) 51(49%) 28(64%) 26(53%)
Prenatal Dxa Y 20(67%) 57(83%) 79(77%) 86(82%) 33(75%) 37(76%)
N 10(33%) 12(17%) 24(23%) 19(18%) 11(25%) 12(24%)
Aortic atresia Y 19(63%) 42(61%) 67(65%) 57(54%) 23(52%) 35(71%)
N 11(37%) 27(39%) 36(35%) 48(46%) 21(48%) 14(29%)
Obstructed pulmonary venous return Y 1(3%) 1(2%) 2(2%) 1(1%) 0(0%) 1(2%)
N 29(97%) 68(98%) 101(98%) 104(99%) 44(100%) 48(98%)
Continuousb
Birth weight (grams) 3160(452) 3228(455) 3141(492) 3146(561) 3159(619) 3114(514)
Norwood age (days) 7.3(3.5) 7.2(3.5) 6.2(3.8) 6.9(4.6) 6.6(4.6) 6.6(3.3)
Norwood discharge age (days) 45(22) 37(25) 38(30) 37(28) 48(43) 47(49)
aPrenatal diagnosis of congenital heart disease
bValues given as mean(SD)
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Table A.2: Descriptive statistics by outcome of the Norwood procedure
Variables Elective S2P (n=263) Non-elective S2P (n=137) Death/Tx a(n=148)
Discrete
Sex M 161(61.2%) 91(66.4%) 87(58.8%)
F 102(38.8%) 46(33.6%) 61(41.2%)
Race White 207(78.7%) 116(84.7%) 112(75.7%)
Black 46(17.5%) 13(9.5%) 27(18.2%)
Other 10(3.8%) 8(5.8%) 9(6.1%)
Norwood treatment MBTS 124(47.2%) 53(38.7%) 91(61.5%)
RVPA 139(52.8%) 84(61.3%) 57(38.5%)
Prenatal diagnosis of congenital heart disease Y 206(78.3%) 106(77.4%) 107(72.3%)
N 57(21.7%) 31(22.6%) 41 (27.7%)
Aortic atresia Y 161(61.2%) 82(59.9%) 99(66.9%)
N 102(38.8%) 55(40.1%) 49(33.1%)
Obstructed pulmonary venous return Y 4(1.5%) 2(1.5%) 13(8.8%)
N 259(98.5%) 135(98.5%) 135(91.2%)
Continuousb
Birth weight (grams) 3193(535) 3088(478) 2961(576)
Norwood age (days) 6.9(4.4) 6.4(3.0) 6.8(4.2)
Norwood discharge age (days) 38.8(30.2) 42.7(37.5) 42.1(46.1)
aDeath or heart transplantation
bValues given as mean(SD)
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Table A.3: 1-year estimated post-S2P mortality risk by S2P time
S2P time Z 1-yr mortality risk(%) Lower 95% CI Upper 95% CI
1 (1-3 months) 12.10 8.70 15.37
2 (4 months) 10.11 7.25 12.89
3 (5 months) 8.44 6.04 10.78
4 (6 months) 3.70 2.63 4.76
5 (7 months) 4.24 3.01 5.46
6 (≥ 8 months) 4.86 3.46 6.25
A.3.
We show that when censoring is noninformative and there are no unmeasured con-
founders, the estimate α̂ obtained by solving Equations (1.5) and (1.6) is consistent for α
in Model (1.4).
Define the counting process Ni(t) = I(T ∗i ≤ t,∆i = 1), where I(·) is the indicator
function, T ∗i is the observed post-S2P follow-up time for subject i, and ∆i is an indicator
that equals 1 if subject i dies after S2P and 0 otherwise. Denote ξi(t) to be the indicator
that subject i is at risk at time t.
Consider a hypothetical randomized study in which the treatment (S2P timing) is ran-
domly assigned under distribution f(z), where z is discrete as in this study. The score


















Here, A(·) is the design matrix under the linear spline model with knots K. The score







i , Zi;α) = 0 is an unbiased estimator of
ER{U∗(T ∗, Z;α)}, where ER{·} refers to expectation under the hypothetical randomized
study [26]. Murphy et al [29] derived the Radon-Nikodym derivative for the distribution of
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the data from a hypothetical randomized study with respect to the distribution of the data
from an observational study under the no-unmeasured-confounder assumption.
One can obtain unbiased estimating equations for α in the observational study by
weighting the terms according to their Radon-Nikodym derivatives under the hypothetical
randomized study [26]. Suppose the probability distribution of the data (T ∗, Z,X,∆) under
the hypothetical distribution is PrR(·) and under the observational study is Pr(·). Murphy
et al [29] have shown that the distribution of (T ∗, Z,X,∆) under PrR(·) is absolutely con-
tinuous with respect to the distribution of (T ∗, Z,X,∆) under Pr(·) with a Radon-Nikodym
derivative. Because the S2P treatment censored by death or heart transplantation is





∗ = t, Z = z,X = x,∆ = δ
}
, where E{·} is the expectation under the
observational study. Now,
ER{U∗(T ∗, Z;α)} = E
{
U∗(T ∗, Z;α)× f(z)
f(z|x)
}
= E{U(T ∗, Z;α)}
where U(T ∗, Z;α) := U∗(T ∗, Z;α) × f(z)
f(z|x) = U
∗(T ∗, Z;α) × w∗ and U(T ∗, Z;α) is the
score function of Model (1.4) for the observational study. We estimate f(z|x) from the
discrete-time competing-risk model and use it to compute the generalized propensity




























i , Zi;α) = 0, which is identical to the estimating equations in (1.5)
and (1.6), we obtain a consistent estimate for α in Model (1.4) [26].
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A.4.
To estimate frequentist properties of the parameter estimates, we repeat the following
procedures 2,000 times. In each iteration, we generate a data set, then apply our method
to the data set and record the estimates. Each simulation consists of five steps:
1. Consistent with our application to the SVRT data, we bootstrap the real data set with
the desired sample size (n = 500 or n = 1000). We only keep the baseline covariates
X and the post-Norwood event type R (signifying elective S2P, non-elective S2P,
death, or heart transplantation).
2. Plugging the observed x and r into the generalized propensity score model es-
timated from the real data, we obtain the probability Pr(Z, r|x). We sample the
Norwood outcome event time Z from the distribution with probability mass function
Pr(Z, r|x).
3. We sample post-S2P survival from a standard parametric distribution, as indicated
in Table 1.3. We simulate the post-S2P survival time T under the spline model
estimated from the real data for the corresponding R.
4. The censoring of post-S2P survival is administrative. Thus we censor the simulated
survival time T at a designated censoring time C.
5. We apply our proposed analyses to the above generated data.
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APPENDIX B
APPENDIX of CHAPTER 2
We provide here the form of the log-likelihood function in the restricted cubic spline
model.
The cumulative hazard Λi(u, zi) at post-S2P time u with treatment zi for subject i is:





















Bj(u) is the integral of Bj(u), where B0(u) = u and, for j = 1, . . . , J − 2,








The full log-likelihood is then





























































where n∗ is the number of patients who underwent S2P; t∗i is the observed value of T ∗i ;
and di is the observed value of Di for subject i.
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APPENDIX C
APPENDIX of CHAPTER 3
Figure C.1: Calibration plots for VA women ASCVD risk model 2 by race
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